Ledipasvir/Sofosbuvir: Generic Harvoni Cost, Genotypes, and Access

Ledipasvir/sofosbuvir is the generic name for Harvoni, one of the drugs that made hepatitis C curable with a single daily tablet. If you are researching it, the two things that matter most are which genotypes it treats and how to get it affordably — because a “cheaper generic” is only a bargain if it is the right medicine for your infection.

This is SunnyPharma’s independent, physician-reviewed guide to ledipasvir/sofosbuvir: what it is, the genotypes it covers, how it compares to pan-genotypic Epclusa, what it costs in the U.S., and how cost-burdened patients reach it at low or no cost.

What Ledipasvir/Sofosbuvir Is

Ledipasvir/sofosbuvir is a fixed-dose combination of two direct-acting antivirals in a single tablet. Ledipasvir is an NS5A inhibitor and sofosbuvir is an NS5B polymerase inhibitor; together they block two steps the hepatitis C virus needs to replicate. It is sold as the brand Harvoni, and since 2019 as an FDA-approved authorized generic from Asegua Therapeutics, a Gilead subsidiary. When it launched in 2014, it was one of the first regimens to make hepatitis C curable without interferon injections.

Which Genotypes It Treats — and Why That Comes First

Hepatitis C comes in six main genotypes, and this is the single most important thing to understand about ledipasvir/sofosbuvir before you think about price. A simple blood test identifies your genotype, and it determines whether this drug is even appropriate for you.

Ledipasvir/sofosbuvir mainly treats genotypes 1, 4, 5, and 6. It is not a first-line choice for genotypes 2 or 3. That is a hard clinical limit, not a preference — if you have genotype 2 or 3, a “cheaper” generic Harvoni is the wrong medicine, and taking it risks a failed cure and wasted months. This is where pan-genotypic drugs come in.

Genotype coverage per FDA labeling and AASLD-IDSA HCV guidance. Your prescriber confirms the right regimen for your genotype and liver status.

Is Ledipasvir/Sofosbuvir Still Used?

It is still used and still effective — but it is no longer the automatic first choice. When pan-genotypic regimens like sofosbuvir/velpatasvir (Epclusa) and glecaprevir/pibrentasvir (Mavyret) arrived, they simplified treatment: one regimen for every genotype, so a patient could often start therapy before genotype results even came back. Many treatment guidelines now lead with those.

That does not make ledipasvir/sofosbuvir obsolete. For a patient with genotype 1, 4, 5, or 6 — especially where a generic version is the lowest-cost option their coverage allows — it remains a legitimate, high-cure-rate cure. The point is simply that the choice should be driven by your genotype and your coverage, decided with your prescriber, rather than by chasing the cheapest generic you can find online.

What It Costs in the U.S.

Brand Harvoni carried one of the most talked-about price tags in modern medicine — on the order of $94,500 for a 12-week course at launch-era list prices. The authorized generic is dramatically cheaper than that, but a generic course still runs into the thousands of dollars in cash terms. As with every hepatitis C drug, though, the sticker price is rarely what a cost-burdened patient actually pays.

Prices approximate, 2026. Actual cost depends on plan design, pharmacy, and assistance eligibility.

The practical takeaway matches every other hepatitis C drug: your coverage matters more than the price tag. Before treating the generic’s cash price as your answer, check whether you qualify to pay $0 through Support Path, Medicaid, or a foundation.

The Global Generic and Buying Safely

As with sofosbuvir/velpatasvir, Gilead licensed India-based manufacturers to produce low-cost generic ledipasvir/sofosbuvir for distribution across many lower-income countries through the Medicines Patent Pool framework, which is why you may see strikingly low prices online. Those versions are made for other markets, are not FDA-approved for U.S. sale, and generally cannot be legally imported for personal use.

The gap between U.S. and overseas prices is also where counterfeiters operate. If you are weighing an online purchase, remember that a real cure requires a prescription and a genotype test, that hepatitis B screening must happen first because treatment can reactivate hepatitis B, and that legitimate pharmacies can show their sourcing while anonymous checkout pages cannot. The safer sequence is to price the FDA-approved generic and check assistance programs before considering an overseas seller.

Side Effects and Safety

Ledipasvir/sofosbuvir is generally well tolerated. The most common side effects are mild — fatigue and headache. A few points carry more weight:

• Hepatitis B reactivation (boxed warning). In anyone who has ever had hepatitis B, curing hepatitis C can reactivate the hepatitis B virus and cause serious liver injury. Everyone is screened for hepatitis B before treatment.
• Acid-reducing drugs matter. Antacids, H2 blockers, and proton pump inhibitors can reduce how much ledipasvir your body absorbs, which can lower the chance of cure. Tell your prescriber about every acid-reducing medicine you take so timing and dosing can be managed.
• Amiodarone interaction. Like other sofosbuvir-based regimens, combining it with the heart-rhythm drug amiodarone can cause a dangerously slow heart rate and is generally avoided.

Frequently Asked Questions